Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
03/08/2023 | 22:15 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ABCL | AbCellera Biologics Inc |
03/08/2023 | 22:05 | Business Wire | AbCellera Reports Q2 2023 Business Results | NASDAQ:ABCL | AbCellera Biologics Inc |
24/07/2023 | 22:05 | Business Wire | AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing | NASDAQ:ABCL | AbCellera Biologics Inc |
06/07/2023 | 22:05 | Business Wire | AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
30/05/2023 | 19:15 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ABCL | AbCellera Biologics Inc |
29/05/2023 | 22:05 | Business Wire | AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
24/05/2023 | 19:10 | Business Wire | AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients | NASDAQ:ABCL | AbCellera Biologics Inc |
04/05/2023 | 23:01 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:ABCL | AbCellera Biologics Inc |
04/05/2023 | 22:41 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ABCL | AbCellera Biologics Inc |
04/05/2023 | 22:05 | Business Wire | AbCellera Reports Q1 2023 Business Results | NASDAQ:ABCL | AbCellera Biologics Inc |
28/04/2023 | 23:02 | Edgar (US Regulatory) | Annual Report to Security Holders (ars) | NASDAQ:ABCL | AbCellera Biologics Inc |
17/04/2023 | 15:10 | Business Wire | AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
11/04/2023 | 22:05 | Business Wire | AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
06/04/2023 | 22:05 | Business Wire | AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
22/03/2023 | 14:00 | Business Wire | AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease | NASDAQ:ABCL | AbCellera Biologics Inc |
14/03/2023 | 21:30 | Business Wire | AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
23/02/2023 | 22:05 | Business Wire | AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
21/02/2023 | 22:05 | Business Wire | AbCellera Reports Full Year 2022 Business Results | NASDAQ:ABCL | AbCellera Biologics Inc |
13/02/2023 | 20:50 | Edgar (US Regulatory) | Schedule 13g (sc 13g/a) | NASDAQ:ABCL | AbCellera Biologics Inc |
06/02/2023 | 22:32 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:ABCL | AbCellera Biologics Inc |
01/02/2023 | 22:05 | Business Wire | AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
24/01/2023 | 22:05 | Business Wire | AbCellera to Report Full Year 2022 Financial Results on February 21, 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
20/01/2023 | 01:00 | Business Wire | AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent | NASDAQ:ABCL | AbCellera Biologics Inc |
04/01/2023 | 22:05 | Business Wire | AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
15/12/2022 | 13:00 | Business Wire | AbCellera and AbbVie Partner to Advance New Antibody Therapies | NASDAQ:ABCL | AbCellera Biologics Inc |
01/12/2022 | 20:35 | TipRanks | AbCellera Biologics (ABCL) Gets a Buy from Berenberg Bank | NASDAQ:ABCL | AbCellera Biologics Inc |
01/12/2022 | 13:00 | Business Wire | AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases | NASDAQ:ABCL | AbCellera Biologics Inc |
10/11/2022 | 14:05 | Business Wire | AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022 | NASDAQ:ABCL | AbCellera Biologics Inc |
09/11/2022 | 12:15 | TipRanks | Berenberg Bank Remains a Buy on AbCellera Biologics (ABCL) | NASDAQ:ABCL | AbCellera Biologics Inc |
08/11/2022 | 22:05 | Business Wire | AbCellera Reports Q3 2022 Business Results | NASDAQ:ABCL | AbCellera Biologics Inc |